Statins and downstream inhibitors of the isoprenylation pathway increase type 2 iodothyronine deiodinase activity.
Statins and downstream inhibitors of the isoprenylation pathway increase type 2 iodothyronine deiodinase activity. Endocrinology. 2012 Aug; 153(8):4039-48.